VIP and growth factors in the infected cornea

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6154-6161

  Jiang, Xiaoyu ^a   McClellan, Sharon A ^a   Barrett, Ronald P ^a   Berger, Elizabeth A ^a   Zhang, Yunfan ^a   Hazlett, Linda D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 3; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CELL ACTIVITY; CONTROLLED STUDY; CORNEA PERFORATION; DOWN REGULATION; DRUG MECHANISM; EPITHELIUM CELL; FEMALE; KERATITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STROMA CELL; UPREGULATION;

ANIMALS; COLONY COUNT, MICROBIAL; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL PERFORATION; CORNEAL ULCER; CYTOKINES; DEFENSINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE INFECTIONS, BACTERIAL; FEMALE; GENE EXPRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; PSEUDOMONAS INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 80051504332     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6943     Document Type: Article

References (38)

1. Cavanaugh HD, Robertson DM, Petroll WM, Jester JV. Castroviejo lecture 2009: 40 years in search of the perfect contact lens. Cornea. 2010;10:1075-1085.
2. Kernacki KA, Barrett RP, Hobden JA, Hazlett LD. Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection. J Immunol. 2000;164: 1037-1045.
3. Moon MM, Hazlett LD, Hancock RE, Berk RS, Barrett R. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 1988;29:1277-1284.
4. Iglewski BH, Burns RP, Gipson IK. Pathogenesis of corneal damage from pseudomonas exotoxin A. Invest Ophthalmol Vis Sci. 1977; 16:73-76.
5. Pillar CM, Hobden JA. Pseudomonas aeruginosa exotoxin A and keratitis in mice. Invest Ophthalmol Vis Sci. 2002;43:1437-1444.
6. Hazlett LD, McClellan S, Kwon B, Barrett R. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive. Invest Ophthalmol Vis Sci. 2000;41:805-810.
7. Szliter EA, Lighvani S, Barrett RP, Hazlett LD. Vasoactive intestinal peptide balances pro-and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation. J Immunol. 2007;178:1105-1114.
8. Weigent DA, Blalock JE. Interactions between the neuroendocrine and immune systems: common hormones and receptors. Immunol Rev. 1987;100:79-108.
9. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004; 56:249-290.
10. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162:1200-1205.
11. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116-129.
12. Rudner XL, Kernacki KA, Barrett RP, Hazlett LD. Prolonged elevation of IL-1 in Pseudomonas aeruginosa ocular infection regulates macrophage-inflammatory protein-2 production, polymorphonuclear neutrophil persistence, and corneal perforation. J Immunol. 2000;164:6576-6582.
13. Hazlett LD, Moon MM, Strejc M, Berk RS. Evidence for N-acetylmannosamine as an ocular receptor for P. aeruginosa adherence to scarified cornea. Invest Ophth Vis Sci. 1987;28:1978-1985.
14. Wu M, McClellan SA, Barrett RP, Hazlett LD. Beta-defensin-2 promotes resistance against infection with P. aeruginosa. J Immunol. 2009;182:1609-1616.
15. Wu M, McClellan SA, Barrett RP, Zhang Y, Hazlett LD. Beta-defensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis. J Immunol. 2009;183:8054-8060.
16. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
17. Forster CG, Cursiefen C, Kruse FE. Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment. Ophthalmologe. 2008;105:269-273.
18. Fredj-Reygrobellet D, Plouet J, Delayre T, Baudouin C, Bourret F, Lapalus P. Effects of aFGF and bFGF on wound healing in rabbit corneas. Curr Eye Res. 1987;6:1205-1209.
19. Baldwin HC, Marshall J. Growth factors in corneal wound healing following refractive surgery: A review. Acta Ophthalmol Scand. 2002;80:238-247.
20. Gressens P, Paindaveine B, Hill JM, Brenneman DE, Evrard P. Growth factor properties of VIP during early brain development. Whole embryo culture and in vivo studies. Ann N Y Acad Sci. 1997;814:152-160.
21. Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul Pept. 2007;144:101-108.
22. Hill JM, Mehnert J, McCune SK, Brenneman DE. Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides. 2002;23:1803-1808.
23. Bertelsen LS, Barrett KE, Keely SJ. Gs protein-coupled receptor agonists induce transactivation of the epidermal growth factor receptor in T84 cells: implications for epithelial secretory responses. J Biol Chem. 2004;279:6271-6279.
24. Zhang JS, Tan YR, Xiang Y, Luo ZQ, Qin XQ. Regulatory peptides modulate adhesion of polymorphonuclear leukocytes to bronchial epithelial cells through regulation of interleukins, ICAM-1 and NF-kappaB/IkappaB. Acta Biochim Biophys Sin (Shanghai). 2006; 38:119-128.
25. Buret A, Olson ME, Gall DG, Hardin JA. Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits. Infect Immun. 1998;66:4917-4923.
26. Viget NB, Guery BP, Ader F, et al. Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1199-L1209.
27. Erdag G, Medalie DA, Rakhorst H, Krueger GG, Morgan JR. FGF-7 expression enhances the performance of bioengineered skin. Mol Ther. 2004;10:76-85.
28. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: Targeting the inflamed vascular endothelium. J Am Soc Nephrol. 2006;17:2464-2473.
29. Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, Liu Y. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am J Pathol. 2008;173: 30-41.
30. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
31. Hong YK, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004;18: 1111-1113.
32. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028-1043.
33. Tille JC, Wood J, Mandriota SJ, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF-and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001;299:1073-1085.
34. Nicosia RF. What is the role of vascular endothelial growth factorrelated molecules in tumor angiogenesis? Am J Pathol. 1998;153: 11-16.
35. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103:11405-11410.
36. Streilein JW. Ocular immune privilege: Therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879-889.
37. Hu DE, Hiley CR, Fan TP. Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and-3 and angiotensin II in a rat sponge model. Br J Pharmacol. 1996;117: 545-551.
38. Nishida T, Nakamura M, Murakami J, Mishima H, Otori T. Epidermal growth factor stimulates corneal epithelial cell attachment to fibronectin through a fibronectin receptor system. Invest Ophthalmol Vis Sci. 1992;33:2464-2469.